Comparison
17 20 Lyase Deficiency Isolated C3277849 vs 11q22 2q22 3 Microdeletion Syndrome C5680062
Clinical comparison between 17 20 Lyase Deficiency Isolated and 11q22 2q22 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 20 Lyase Deficiency Isolated C3277849
A rare enzymatic disorder affecting sex hormone production. Impairs development of sexual characteristics in both males and females. Treatment involves hormone supplementation.
11q22 2q22 3 Microdeletion Syndrome C5680062
A rare genetic condition where a small segment of chromosome 11 is missing. It can affect development and cause various health concerns. Treatment focuses on managing specific symptoms with supportive care.
6 comparison axes
Onset
17 20 Lyase Deficiency Isolated C3277849
0-18
11q22 2q22 3 Microdeletion Syndrome C5680062
0-null
Onset patterns differ
Severity
17 20 Lyase Deficiency Isolated C3277849
severe
11q22 2q22 3 Microdeletion Syndrome C5680062
moderate
Different severity levels
Chronic
17 20 Lyase Deficiency Isolated C3277849
Chronic
11q22 2q22 3 Microdeletion Syndrome C5680062
Chronic
Differing course
Communicable
17 20 Lyase Deficiency Isolated C3277849
No
11q22 2q22 3 Microdeletion Syndrome C5680062
No
Different transmission
Body System
17 20 Lyase Deficiency Isolated C3277849
endocrine
11q22 2q22 3 Microdeletion Syndrome C5680062
congenital
Same/different system
Category
17 20 Lyase Deficiency Isolated C3277849
endocrine
11q22 2q22 3 Microdeletion Syndrome C5680062
genetic
Different category
Bottom line
17-20-lyase-deficiency-isolated-C3277849 and 11q22-2q22-3-microdeletion-syndrome-C5680062 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 20 Lyase Deficiency Isolated C3277849 | 11q22 2q22 3 Microdeletion Syndrome C5680062 | Discriminating power |
|---|---|---|---|
| Sexual development | Impaired sex-steroid production may alter puberty or sexual characteristics. | Sexual development is not the defining feature; findings vary. | High |
| Development | Neurodevelopment is not established as a core feature. | Developmental concerns may occur, but the pattern is variable. | Moderate |
| Congenital features | Primarily an enzymatic endocrine disorder, not a deletion syndrome. | A missing chromosome 11 segment may cause variable health concerns. | High |
When to favor each condition
Choose 17 20 Lyase Deficiency Isolated C3277849 when
Suspected sex-steroid deficiency affecting puberty
This fits an enzymatic hormone disorder better than a chromosomal deletion.
Moderate
Steroid profile suggests impaired 17,20-lyase activity
Supports the endocrine diagnosis, but confirmation is required.
Moderate
Genetic testing implicates the steroidogenic pathway
A relevant variant distinguishes it from a chromosomal microdeletion.
High
Choose 11q22 2q22 3 Microdeletion Syndrome C5680062 when
Microarray detects an 11q22.2-q22.3 deletion
A confirmed deletion directly supports this syndrome.
High
Early developmental concerns without primary steroid abnormality
This is more consistent with a variable genetic condition.
Moderate
Prenatal or family testing identifies the deletion
This establishes a congenital chromosomal cause.
High
How key tests differ
| Test | 17 20 Lyase Deficiency Isolated C3277849 | 11q22 2q22 3 Microdeletion Syndrome C5680062 | Interpretation |
|---|---|---|---|
| Steroid profile | May show reduced sex steroids; exact cutoffs are not established here. | No characteristic steroid pattern is established. | Abnormal steroids suggest an endocrine disorder but are not diagnostic alone. |
| Chromosomal microarray | Expected normal unless an unrelated variant exists. | May detect the 11q22.2-q22.3 deletion. | A confirmed deletion supports the syndrome but does not diagnose lyase deficiency. |
| Gene sequencing | May identify a variant affecting 17,20-lyase function. | Single-gene testing may miss a chromosomal deletion. | Choose testing according to the suspected mechanism. |
Prognosis comparison
17 20 Lyase Deficiency Isolated C3277849
- Outcome
- Chronic endocrine condition; outcome depends on hormone management and associated features.
- Factors
- Puberty management, bone health, fertility concerns, and follow-up.
11q22 2q22 3 Microdeletion Syndrome C5680062
- Outcome
- Chronic congenital condition with variable outcome; uniform prognosis is not established.
- Factors
- Deletion extent, developmental needs, organ involvement, and supportive care.
Time frame: Needs may extend from childhood into adulthood and change over time.
Confirmed diagnosis, associated findings, specialist care, and individualized support.
Complications comparison
| Complication | Presentation |
|---|---|
| Hormone deficiency | May affect puberty, fertility, or bone health. Not an established defining complication. Hormone needs require specialist monitoring. |
| Developmental concerns | Not established as typical. Variable learning, developmental, or organ concerns may occur. Do not assume a phenotype from the deletion label alone. |
| Care burden | Long-term hormone supplementation and monitoring may be needed. Supportive care depends on individual findings. Neither condition has a universal complication profile here. |
Patient education highlights
- HighResult versus diagnosis
An abnormal hormone or genetic result needs clinician interpretation and confirmation.
- HighTreatment approach
The endocrine disorder generally uses hormone care; the deletion uses symptom-specific support.
- MediumFamily questions
Discuss inheritance and testing with a genetics clinician before drawing conclusions.